Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau

Reuters

Sep 12

Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau

Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced a significant milestone in the commercialization of its Core Product for the treatment of type 2 diabetes. The company has received regulatory approval for its biologics license application (BLA) in the Macau Special Administrative Region of China. As of September 12, 2025, the first prescription for the product, Efsubaglutide Alfa, has been issued at Centro Médico HB in Macau, marking the official commencement of its commercial sale in the region. The company, however, cautions that successful market penetration is not guaranteed and advises shareholders and potential investors to exercise due care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566980974"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566980974\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566980974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566980974","market":"fut","top_or_hot":-1,"title":"Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced a significant milestone in the commercialization of its Core Product for the treatment of type 2 diabetes. The company has received regulatory approval for its biologics license application (BLA) in the Macau Special Administrative Region of China. As of September 12, 2025, the first prescription for the product, Efsubaglutide Alfa, has been issued at Centro Médico HB in Macau, marking the official commencement of its commercial sale in the region. The company, however, cautions that successful market penetration is not guaranteed and advises shareholders and potential investors to exercise due care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced a significant milestone in the commercialization of its Core Product for the treatment of type 2 diabetes. The company has received regulatory approval for its biologics license application (BLA) in the Macau Special Administrative Region of China. As of September 12, 2025, the first prescription for the product, Efsubaglutide Alfa, has been issued at Centro Médico HB in Macau, marking the official commencement of its commercial sale in the region. The company, however, cautions that successful market penetration is not guaranteed and advises shareholders and potential investors to exercise due care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL8zS8J2:1","article_id":"2566980974","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566980974","pubTimestamp":1757682402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced a significant milestone in the commercialization of its Core Product for the treatment of type 2 diabetes. The company has received regulatory approval for its biologics license application  in the Macau Special Administrative Region of China. As of September 12, 2025, the first prescription for the product, Efsubaglutide Alfa, has been issued at Centro Médico HB in Macau, marking the official commencement of its commercial sale in the region. The company, however, cautions that successful market penetration is not guaranteed and advises shareholders and potential investors to exercise due care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02591":"银诺医药－Ｂ"},"translate_title":"广州英诺健药业集团有限公司在澳门的核心糖尿病治疗获得监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":0.9},"content_text":"Guangzhou Innogen Pharmaceutical Group Co. Ltd. Receives Regulatory Approval for Core Diabetes Treatment in Macau\n    \n\n        Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced a significant milestone in the commercialization of its Core Product for the treatment of type 2 diabetes. The company has received regulatory approval for its biologics license application (BLA) in the Macau Special Administrative Region of China. As of September 12, 2025, the first prescription for the product, Efsubaglutide Alfa, has been issued at Centro Médico HB in Macau, marking the official commencement of its commercial sale in the region. The company, however, cautions that successful market penetration is not guaranteed and advises shareholders and potential investors to exercise due care.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}